{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:29:31Z","timestamp":1761488971056},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,13]]},"DOI":"10.1097\/qad.0b013e328358b279","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T16:34:40Z","timestamp":1344443680000},"page":"2165-2174","source":"Crossref","is-referenced-by-count":15,"title":["Zidovudine\/lamivudine but not nevirapine in combination with lopinavir\/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA"],"prefix":"10.1097","volume":"26","author":[{"given":"Eoin R.","family":"Feeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit G.A.","family":"van Vonderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven A.","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel A.","family":"van Agtmael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-5-20210130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"R4-5-20210130","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.","volume":"16","author":"Joly","year":"2002","journal-title":"AIDS"},{"key":"R6-5-20210130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00002030-200403260-00015","article-title":"Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy.","volume":"18","author":"Hammond","year":"2004","journal-title":"AIDS"},{"key":"R7-5-20210130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/135965350801300511","article-title":"Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.","volume":"13","author":"McComsey","year":"2008","journal-title":"Antivir Ther"},{"key":"R8-5-20210130","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2337\/db11-0075","article-title":"Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy.","volume":"60","author":"Sevastianova","year":"2011","journal-title":"Diabetes"},{"key":"R9-5-20210130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","article-title":"Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"R10-5-20210130","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00002030-200109280-00009","article-title":"Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.","volume":"15","author":"Shikuma","year":"2001","journal-title":"AIDS"},{"key":"R11-5-20210130","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1086\/424881","article-title":"Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.","volume":"39","author":"Rabing Christensen","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R13-5-20210130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/135965350601100505","article-title":"Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.","volume":"11","author":"Maagaard","year":"2006","journal-title":"Antivir Ther"},{"key":"R14-5-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/QAD.0b013e32833779a3","article-title":"Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease.","volume":"24","author":"Pinti","year":"2010","journal-title":"AIDS"},{"key":"R15-5-20210130","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R16-5-20210130","doi-asserted-by":"crossref","first-page":"F37","DOI":"10.1097\/00002030-199806000-00001","article-title":"Indinavir-associated lipodystrophy.","volume":"12","author":"Viraben","year":"1998","journal-title":"AIDS"},{"key":"R17-5-20210130","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R18-5-20210130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/157016210793499222","article-title":"Differential effects of efavirenz and lopinavirritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines.","volume":"8","author":"Gallego-Escuredo","year":"2010","journal-title":"Curr HIV Res"},{"key":"R19-5-20210130","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","article-title":"The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.","volume":"50","author":"Caron","year":"2001","journal-title":"Diabetes"},{"key":"R20-5-20210130","doi-asserted-by":"crossref","first-page":"41325","DOI":"10.1074\/jbc.M006474200","article-title":"Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors.","volume":"275","author":"Dowell","year":"2000","journal-title":"J Biol Chem"},{"key":"R21-5-20210130","doi-asserted-by":"crossref","first-page":"e5647","DOI":"10.1371\/journal.pone.0005647","article-title":"Zidovudinelamivudine for HIV-1 infection contributes to limb fat loss.","volume":"4","author":"van Vonderen","year":"2009","journal-title":"PLoS One"},{"key":"R22-5-20210130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2125.2003.02020.x","article-title":"Therapeutic drug monitoring of lopinavirritonavir given alone or with a nonnucleoside reverse transcriptase inhibitor.","volume":"57","author":"Solas","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R23-5-20210130","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1086\/429697","article-title":"In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.","volume":"191","author":"Mallon","year":"2005","journal-title":"J Infect Dis"},{"key":"R24-5-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","article-title":"Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.","volume":"19","author":"McComsey","year":"2005","journal-title":"AIDS"},{"key":"R25-5-20210130","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/jac\/dkp100","article-title":"Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.","volume":"63","author":"Gerschenson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R26-5-20210130","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.","volume":"292","author":"Fleischman","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R27-5-20210130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.","volume":"45","author":"Dube","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-5-20210130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"R29-5-20210130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jac\/dkm029","article-title":"Exploratory study comparing the metabolic toxicities of a lopinavirritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavirritonavir plus zidovudinelamivudine nucleoside regimen.","volume":"59","author":"Cameron","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R30-5-20210130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/135965350501000810","article-title":"In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.","volume":"10","author":"Miro","year":"2005","journal-title":"Antivir Ther"},{"key":"R31-5-20210130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1086\/422602","article-title":"Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.","volume":"190","author":"Hoy","year":"2004","journal-title":"J Infect Dis"},{"key":"R32-5-20210130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1468-1293.2011.00934.x","article-title":"Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).","volume":"12","author":"Feeney","year":"2011","journal-title":"HIV Med"},{"key":"R33-5-20210130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0b013e3181568e3f","article-title":"Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.","volume":"46","author":"Wester","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-5-20210130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00126334-200309010-00008","article-title":"Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns.","volume":"34","author":"Galli","year":"2003","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201211130-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T06:51:31Z","timestamp":1687675891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201211130-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,13]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328358b279","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,13]]}}}